408: Whistleblower takes on health insurance and FDA commissioner candidates

The episode opens with weekly biotech news, including updates on FDA commissioner candidates, Vertex's $10 billion acquisition of Krenetics, Anthropic's new drug development and AI research tool Claude Science, and AstraZeneca's failed ATTR-CM drug trial. The main focus shifts to the affordability crisis in employer-based health insurance, which covers more than 150 million Americans. Bob Herman, a STAT reporter, discusses his new investigative series "Out of Pocket, Out of Reach," examining why employer health coverage has become increasingly unaffordable. Herman explains that health insurance premiums are rising much faster than wages and inflation, with family coverage costing approximately the price of a new car annually. He identifies the root cause as systematically high prices across the entire U.S. healthcare system—hospitals, medical groups, and drug companies all charge the highest prices globally, which insurers then cover at a premium. Employers lack meaningful negotiating power and are forced to accept these costs. Herman documents how small businesses (50 or fewer employees) are disproportionately affected, with many abandoning health coverage entirely due to unaffordable costs, while some workers are incentivized to take cash instead of coverage or purchase plans through the Affordable Care Act exchanges. The expiration of pandemic-era ACA subsidies has further compounded affordability challenges for workers seeking alternative coverage. Larger employers have attempted various cost-control strategies—such as self-insurance, steering employees to specific hospitals, and increasing deductibles—but these approaches have yielded minimal results in controlling overall healthcare spending. The episode features a primary interview with Chris Deacon, a New Jersey health benefits administrator who filed a whistleblower lawsuit against Horizon Blue Cross Blue Shield, alleging fraud and contract violations. The state eventually settled for $100 million in November 2023, but Deacon was excluded from the settlement agreement as a condition of the deal, losing her whistleblower designation despite four and a half years of work on the case. Deacon argues that employers are complicit in rising costs through their unwillingness to challenge the status quo and question vendor practices, even when uncomfortable. She contends that complexity in the healthcare system is deliberately leveraged by the industry to prevent employer intervention. Deacon emphasizes that healthcare spending is actionable through employer decisions and criticizes the acceptance of double-digit rate increases as inevitable. She advocates for earlier planning cycles in insurance renewals, demanding contracts before January 1st rather than negotiating during the standard renewal periods, and addressing underlying unit costs rather than implementing peripheral cost-control measures. Deacon acknowledges that transparency and the defensive posturing of carriers represent progress in the national conversation about healthcare costs, giving her cautious optimism about future change.